Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 2
Submit an article Journal homepage
166
Views
0
CrossRef citations to date
0
Altmetric
Review

Design of Inhibitors of Odcase

Sourabh Mundra1 Center for Molecular Design & Preformulations, & Toronto General Research Institute, University Health Network, Toronto, Ontario, M5G 1L7, Canada;2 Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, IndiaView further author information
&
Lakshmi P Kotra1 Center for Molecular Design & Preformulations, & Toronto General Research Institute, University Health Network, Toronto, Ontario, M5G 1L7, Canada;3 Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, M5S 3M2, Canada. [email protected]Correspondence[email protected]
View further author information
Pages 165-177 | Published online: 28 Jan 2014

References

  • Reichard P . The enzymatic synthesis of pyrimidines.Adv. Enzymol. Mol. Biol.21, 263–294 (1959).
  • Callahan BP , MillerBG. OMP decarboxylase-An enigma persists.Bioorg. Chem.35(6), 465–469 (2007).
  • Radzicka A , WolfendenR. A proficient enzyme.Science267(5194), 90–93 (1995).
  • Lewis CA Jr, Wolfenden R. Uroporphyrinogen decarboxylase as a benchmark for the catalytic proficiency of enzymes. Proc. Natl. Acad. Sci. U S A105(45), 17328–17333 (2008).
  • Jordan F , PatelH. Catalysis in enzymatic decarboxylations: comparison of selected cofactor-dependent and cofactor-independent examples.ACS Catal.3(7), 1601–1617 (2013).
  • Donovan WP , KushnerSR. Purification and characterization of orotidine-5´-monophosphate decarboxylase from Escherichia coli K-12. J. Bacteriol.156(2), 620–624 (1983).
  • Pragobpol S , GeroAM, LeeCS, O‘SullivanWJ. Orotate phosphoribosyltransferase and orotidylate decarboxylase from Crithidia luciliae: subcellular location of the enzymes and a study of substrate channeling. Arch. Biochem. Biophys.230(1), 285–293 (1984).
  • Warshel A , FlorianJ. Computer simulations of enzyme catalysis: finding out what has been optimized by evolution.Proc. Natl Acad. Sci. U S A95(11), 5950–5955 (1998).
  • Miller BG , WolfendenR. Catalytic proficiency: the unusual case of OMP decarboxylase.Annu. Rev. Biochem.71, 847–885 (2002).
  • Meza-Avina ME , WeiL, LiuYet al. Structural determinants for the inhibitory ligands of orotidine-5´-monophosphate decarboxylase. Bioorg. Med. Chem. 18(11), 4032–4041 (2010).
  • Gero AM , O‘SullivanWJ. Purines and pyrimidines in malarial parasites.Blood Cells16(2–3), 467–484 (1990).
  • Reyes P , GuganigME. Pyrimidine phosphoribosyltransferase from murine leukemia P1534J. Partial purification, substrate specificity, and evidence for its existence as a bifunctional complex with orotidine 5-phosphate decarboxylase.J. Biol. Chem.250(13), 5097–5108 (1975).
  • McClard RW , BlackMJ, LivingstoneLR, JonesME. Isolation and initial characterization of the single polypeptide that synthesizes uridine 5´-monophosphate from orotate in Ehrlich ascites carcinoma. Purification by tandem affinity chromatography of uridine- 5´-monophosphate synthase. Biochemistry19(20), 4699–4706 (1980).
  • Meza-Avina ME , WeiL, BuhendwaMG, et al. Inhibition of orotidine 5´-monophosphate decarboxylase and its therapeutic potential. Mini-Rev. Med. Chem.8(3), 239–247(2008).
  • Casper ES , ValeK, WilliamsLJ, MartinDS, YoungCW. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-l-aspartic acid. Cancer Res.43(5), 2324–9 (1983).
  • Beak P , SiegelB. Mechanism of decarboxylation of 1,3-dimethylorotic acid. A model for orotidine 5´-phosphate decarboxylase.J. Am. Chem. Soc.98(12), 3601–3606 (1976).
  • Silverman RB , GroziakMP. Model chemistry for a covalent mechanism of Action of orotidine 5´-phosphate decarboxylase.J. Am. Chem. Soc.104(23), 6434–6439 (1982).
  • Acheson SA , BellJB, JonesME, WolfendenR. Orotidine-5´-monophosphate decarboxylase catalysis: kinetic isotope effects and the state of hybridization of a bound transition-state analogue.Biochemistry29(13), 3198–3202 (1990).
  • Wu N , GillonW, PaiEF. Mapping the active site-ligand interactions of orotidine 5´-monophosphate decarboxylase by crystallography.Biochemistry41(12), 4002–4011 (2002).
  • Feng WY , AustinTJ, ChewF, GronertS, WuW. The mechanism of orotidine 5´-monophosphate decarboxylase: catalysis by destabilization of the substrate.Biochemistry39(7), 1778–1783 (2000).
  • Begley TP , ApplebyTC, EalickSE. The structural basis for the remarkable catalytic proficiency of orotidine 5´-monophosphate decarboxylase.Curr. Opin. Struct. Biol.10(6), 711–718 (2000).
  • Wu N , PaiEF. Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5´-monophosphate decarboxylaseJ. Biol. Chem.277(31), 28080–28087 (2002).
  • Warshel A , StrajblM, VillaJ, FlorianJ. Remarkable rate enhancement of orotidine 5´-monophosphate decarboxylase is due to transition-state stabilization rather than to ground-state destabilization.Biochemistry39(48), 14728–14738 (2000).
  • Wu N , MoY, GaoJ, PaiEF. Electrostatic stress in catalysis: structure and mechanism of the enzyme orotidine monophosphate decarboxylase.Proc. Natl Acad. Sci. U S A97(5), 2017–2022 (2000).
  • Fujihashi M , MitoK, PaiEF, MikiK. Atomic resolution structure of the orotidine 5´-monophosphate decarboxylase product complex combined with surface plasmon resonance analysis: implications for the catalytic mechanism.J. Biol. Chem.288(13), 9011–9016 (2013).
  • Lee JK , HoukKN. A proficient enzyme revisited: the predicted mechanism for orotidine monophosphate decarboxylase.Science276(5314), 942–945 (1997).
  • Lee TS , ChongLT, ChoderaJD, KollmanP. An alternative explanation for the catalytic proficiency of orotidine 5´-phosphate decarboxylase.J. Am. Chem. Soc.123(51), 12837–12848 (2001).
  • Hur S , BruiceTC. Molecular dynamic study of orotidine-5´-monophosphate decarboxylase in ground state and in intermediate state: a role of the 203–218 loop dynamics.Proc. Natl Acad. Sci. U S A99(15), 9668–9673 (2002).
  • Shostak K , JonesME. Orotidylate decarboxylase: insights into the catalytic mechanism from substrate specificity studies.Biochemistry31(48), 12155–12161 (1992).
  • Appleby TC , KinslandC, BegleyTP, EalickSE. The crystal structure and mechanism of orotidine 5´-monophosphate decarboxylase.Proc. Natl Acad. Sci. U S A97(5), 2005–2010, (2000).
  • Toth K , Amyes,TL, WoodBM, ChanK, GerltJA, RichardJP. Product deuterium isotope effects for orotidine 5´-monophosphate decarboxylase: effect of changing substrate and enzyme structure on the partitioning of the vinyl carbanion reaction intermediate.J. Am. Chem. Soc.132, 7018–7024 (2010).
  • Toth K , AmyesTL, WoodBM, ChanK, GerltJA, RichardJP. Product deuterium isotope effect for orotidine 5´-monophosphate decarboxylase: evidence for the existence of a short-lived carbanion intermediate.J. Am. Chem. Soc.129, 12946–12947 (2007).
  • Vardi-Kilshtain A , DoronD, MajorDT. Quantum and classical simulations of orotidine monophosphate decarboxylase: support for a direct decarboxylation mechanism.Biochemistry52(25), 4382–4390 (2013).
  • Amyes TL , WoodBM, ChanK, GerltJA, RichardJP. Formation and stability of a vinyl carbanion at the active site of orotidine 5´-monophosphate decarboxylase: pKa of the C-6 proton of enzyme-bound UMP.J. Am. Chem. Soc.130, 1574–1575 (2008).
  • Tsang WY , WoodBM, WongFMet al. Proton transfer from C-6 of uridine 5´-monophosphate catalyzed by orotidine 5´-monophosphate decarboxylase: formation and stability of a vinyl carbanion intermediate and the effect of a 5-fluoro substituent. J. Am. Chem. Soc. 134, 14580–14594 (2012).
  • Goryanova B , AmyesTL, GerltJA, RichardJP. OMP decarboxylase: phosphodianion binding energy is used to stabilize a vinyl carbanion intermediate.J. Am. Chem. Soc.133(17), 6545–6548 (2011).
  • Chan KK , WoodBM, FedorovAAet al. Mechanism of the orotidine 5´-monophosphate decarboxylase-catalyzed reaction: evidence for substrate destabilization. Biochemistry 48(24), 5518–5531 (2009).
  • Langley DB , ShojaeiM, ChanCet al. Structure and inhibition of orotidine 5´-monophosphate decarboxylase from Plasmodium falciparum. Biochemistry 47(12), 3842–3854 (2008).
  • Wu N , PaiEF. Crystallographic studies of native and mutant orotidine 5´ phosphate decarboxylases.Top. Curr. Chem.238, 23–42 (2004).
  • Amyes TL , RichardJP. Specificity in transition state binding: the Pauling Model revisited.Biochemistry52(12), 2021–2035 (2013).
  • Goryanova B , SpongK, AmyesTL, RichardJP. Catalysis by orotidine 5´-monophosphate decarboxylase: effect of 5-fluoro and 4´-substituents on the decarboxylation of two-part substrates.Biochemistry52(3), 537–546 (2013).
  • Poduch E , WeiL, PaiEF, KotraLP. Structural diversity and plasticity associated with nucleotides targeting orotidine monophosphate decarboxylase.J. Med. Chem.51(3), 432–438 (2008).
  • Purohit MK , PoduchE, WeiLet al. Novel cytidine-based orotidine-5´-monophosphate decarboxylase inhibitors with an unusual twist. J. Med. Chem. 55(22), 9988–9997 (2012).
  • Galmarini CM , PopowickzF, JosephB. Cytotoxic nucleoside analogs: different strategies to improve their clinical efficacy.Curr. Med. Chem.15(11), 1072–1082 (2008).
  • Uga H , KuramoriC, OhtaAet al. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol. Pharmacol. 70(5), 1832–1839 (2006).
  • Bello AM , KonforteD, PoduchEet al. Structure–activity relationships of orotidine-5´-monophosphate decarboxylase inhibitors as anticancer agents. J. Med. Chem. 52(6), 1648–1658 (2009).
  • Chen JJ , JonesME. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydrorotase and dihydroorotase dehydrogenase. J. Biol. Chem.254(11), 4908–4914 (1979).
  • Cadman EC , DixDE, HandschumacherRE. Clinical, biological and biochemical effect of Pyrazofurin.Cancer Res.38(3), 682–698 (1978).
  • Williams RH , GerzonK, HoehnM, GormanM, deLongDC. Abstract# MICR 38, 158th American Chemical Society National Meeting. NY, USA, 7–12 September 1969.
  • Christopherson RI , LyonsSD, WilsonPK. Inhibitors of de novo nucleotide biosynthesis as drugs. Acc. Chem. Res.35, 961 (2002).
  • Sweeney MJ , DavisFA, GutowskiGE, HamillRL, HoffmanDH, PooreGA. Experimental antitumor activity of pyrazomycin.Cancer Res.33(11), 2619–2623 (1973).
  • Gutowski GE , SweeneyMJ, deLongDC, HamillRL, GerzonK. Biochemistry and biological effects of the Pyrazofurins (Pyrazomycins): initial clinical trial.Ann. NY Acad. Sci.255, 544–551 (1975).
  • Ohnuma T , RobozJ, ShapiroML, HollandJF. Pharmacological and biochemical effects of pyrazofurin in humans.Cancer Res.37(7, Pt1), 2043–2049 (1977).
  • Cihak A , VeseleyJ, SkodaJ. Azapyrimidine nucleosides: metabolism and inhibitory mechanism.Adv. Enzyme Regul.24, 335–354 (1985).
  • Miller BG , HassellAM, WolfendenR, MilburnMV, ShortSA. Anatomy of a proficient enzyme: the structure of orotidine 5´- monophosphate decarboxylase in the presence and absence of a potential transition-state analog.Proc. Natl Acad. Sci. U S A97(5), 2011–2016 (2000).
  • Poduch E , BelloAM, TangS, FujihashiM, PaiEF, KotraLP. Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.J. Med. Chem.49(16), 4937–4945 (2006).
  • Smiley JA , SalehL. Active site probes for yeast OMP decarboxylase: inhibition constants of UMP and thio-substituted UMP analogues and greatly reduced activity toward CMP-6-carboxylate.Bioorg. Chem.27(4), 297–300 (1999).
  • Gabrielsen B , KirsiJJ, KwongCDet al. In vitro and in vivo antiviral (RNA) evaluation of orotidine 5´-monophosphate decarboxylase inhibitors and analogs including 6-azauridine-5´-(ethyl methoxyalaninyl)phosphate (a 5´-monophosphate prodrug). Antiviral Chem. Chemother.5(4), 209–220 (1994).
  • Smee DF , McKernanPA, NordLDet al. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob. Agents. Chemother. 31(10), 1535–1541 (1987).
  • Morrey JD , SmeeDF, SidwellRW, TsengC. Identification of active antiviral compounds against a New York isolate of West Nile virus.Antiviral Res.55(1), 107–116 (2002).
  • Andrei G , de Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res.22(1), 45–75 (1993).
  • Wyde PR , GilbertBE, AmbroseMW. Comparison of the anti-respiratory syncytial virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo. Antiviral Res.11(1), 15–26 (1989).
  • de Clercq E . Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.Clin. Microbiol. Rev.14(2), 382–397 (2001).
  • Seymour KK , LyonsSD, PhillipsL, Rieckmann,KH, ChristophersonRI. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry33(17), 5268–5274 (1994).
  • Scott HV , GeroAM, O‘SullivanWJ. In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol. Biochem. Parasitol.18(1), 3–15 (1986).
  • Elgemeie GH , ZagharyWA, AminKM, NasrTM. New trends in synthesis of pyrazole nucleosides as new antimetabolites.Nucleosides Nucleotides Nucleic Acids.24(8), 1227–1247 (2005).
  • Dorsch HM , OsundwaV, LamP. Activation of human B lymphocytes by 8´ substituted guanosine derivatives.Immunol. Lett.17(2), 125–131 (1988).
  • Wicker LS , BoltzRC Jr, Nichols EA, Miller BJ, Sigal NH, Peterson LB. Large activated B cells are the primary B-cell target of 8-bromoguanosine and 8-mercaptoguanosine. Cell. Immunol.106(2), 318–329 (1987).
  • Koo GC , JewellME, ManyakCL, SigalNH, WickerLS. Activation of murine natural killer cells and macrophages by 8-bromoguanosine.J. Immunol.140(9), 3249–3252 (1988).
  • Wicker LS , AshtonWT, BoltzRC Jr et al. 5-halo-6-phenylpyrimidinones and 8-substituted guanosines: biological response modifiers with similar effects on B cells. Cell. Immunol.112(1), 156–165 (1988).
  • Richard KA , MortensenRF, TraceyDE. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo. J. Biol. Response Mod.6(6), 647–663 (1987).
  • Skulnick HI , WeedSD, EidsonEE, RenisHE, WierengaW, StringfellowDA. Pyrimidinones. 1. 2-amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents.J. Med. Chem.28(12), 1864–1869 (1985).
  • Brideau RJ , WolcottJA. Effect of pyrimidinone treatment on lethal and immunosuppressive murine cytomegalovirus infection.Antimicrob. Agents Chemother.28(4), 485–488 (1985).
  • Wierenga W . Antiviral and other bioactivities of pyrimidinones.Pharmacol. Ther.30(1), 67–89 (1985).
  • Goodman MG , HennenWJ. Distinct effects of dual substitution on inductive and differentiative activities of C8-substituted guanine ribonucleosides.Cell. Immunol.102, 395–402 (1986).
  • Reller ME , ChenWH, DaltonJ, LichayMA, DumlerJS. Multiplex 5´ nuclease quantitative real-time PCR for clinical diagnosis of malaria and species-level identification and epidemiologic evaluation of malaria-causing parasites, includingPlasmodium knowlesi. J. Clin. Microbiol.51(9), 2931–2938 (2013).
  • Goh XT , LimYA, VythilingamIet al. Increased detection of Plasmodium knowlesi in Sandakan division, Sabah as revealed by PlasmoNex™. Malar. J. 12, 264 (2013).
  • van Dyke K , TremblayGC, LantzCH, Szustkiewicz,C. The source of purines and pyrimidines inPlasmodium berghei. Am. J. Trop. Med. Hyg.19(2), 202–208 (1970).
  • Sherman IW . Biochemistry of Plasmodium (malarial parasites). Microbiol. Rev.43(4), 453–495 (1979).
  • Scheibel LW , SchermanIW. Malaria: Principles and Practice of Malariology. Wernsdorfer WH, McGreggor I (Eds). Churchill Livingstone, London, UK, 234–242 (1988).
  • Crowther GJ , NapuliAJ, GilliganJHet al. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol. Biochem. Parasitol. 175(1), 21–29 (2011).
  • Seymour KK , LyonsSD, PhillipsL, RieckmannKH, ChristophersonRI. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry33(17), 5268–5274 (1994).
  • Yadav MK , PandeySK, SwatiD. Drug target prioritization in Plasmodium falciparum through metabolic network analysis, and inhibitor designing using virtual screening and docking approach. J. Bioinform. Comput. Biol.11(4), 1350003 (2013).
  • Bello AM , PoduchE, FujihashiMet al. A potent, covalent inhibitor of orotidine 5´-monophosphate decarboxylase with antimalarial activity. J. Med. Chem. 50(5), 915–921 (2007).
  • Bello AM , PoduchE, LiuYet al. Structure-activity relationships of C6-uridine derivatives targeting Plasmodia orotidine monophosphate decarboxylase. J. Med. Chem. 51(3), 439–448 (2008).
  • Fujihashi M , WeiL, KotraLP, PaiEF. Structural characterization of the molecular events during a slow substrate-product transition in orotidine 5´-monophosphate decarboxylase.J. Mol. Biol.387(5), 1199–1210 (2009).
  • Fujihashi M , BelloAM, PoduchEet al. An unprecedented twist to ODCase catalytic activity. J. Am. Chem. Soc. 127, 15048–15050 (2005).
  • Copeland RA . Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. John Wiley and Sons. Inc., Hoboken, NJ, USA (2005).
  • Crandall IE , WasilewskiE, BelloAMet al. Antimalarial activities of 6-iodouridine, itsprodrugs and potential for combination therapy. J. Med. Chem. 56(6), 2348–2358 (2013).
  • Ong HB , SienkiewiczN, WyllieS, PattersonS, FairlambAH. Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy. Mol. Microbiol.90(2), 443–455 (2013).
  • Lewis CA , WolfendenR. Indiscriminate binding by orotidine 5´-phosphate decarboxylase of uridine 5´-phosphate derivatives with bulky anionic C6 substituents.Biochemistry46(46), 13331–13343 (2007).

Patents

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.